Robert Stevens
Director Técnico/Científico/I+D en CorneaGen, Inc. .
Perfil
Robert J.
Stevens is currently a Senior Vice President-Research & Development at CorneaGen, Inc. He previously worked as a Director at Acucela, Inc. Stevens received his undergraduate and graduate degrees from the University of Washington.
Cargos activos de Robert Stevens
| Empresas | Cargo | Inicio |
|---|---|---|
CorneaGen, Inc.
 CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Robert Stevens.
| Empresas | Cargo | Fin |
|---|---|---|
| ACUCELA INC | Director/Miembro de la Junta | - |
Formación de Robert Stevens.
| University of Washington | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
CorneaGen, Inc.
CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Health Technology |
Acucela, Inc.
 Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Stevens
